Optipharm.CO.LTD
Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and c… Read more
Optipharm.CO.LTD - Asset Resilience Ratio
Optipharm.CO.LTD (153710) has an Asset Resilience Ratio of 20.73% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Optipharm.CO.LTD's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Optipharm.CO.LTD's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩8.77 Billion | 20.73% |
| Total Liquid Assets | ₩8.77 Billion | 20.73% |
Asset Resilience Insights
- Good Liquidity Position: Optipharm.CO.LTD maintains a healthy 20.73% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Optipharm.CO.LTD Industry Peers by Asset Resilience Ratio
Compare Optipharm.CO.LTD's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 38.62% |
Annual Asset Resilience Ratio for Optipharm.CO.LTD (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Optipharm.CO.LTD.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 48.50% | ₩21.01 Billion | ₩43.32 Billion | -21.26pp |
| 2023-12-31 | 69.76% | ₩27.40 Billion | ₩39.28 Billion | +5.25pp |
| 2022-12-31 | 64.51% | ₩26.57 Billion | ₩41.18 Billion | -19.11pp |
| 2021-12-31 | 83.63% | ₩34.43 Billion | ₩41.17 Billion | +14.99pp |
| 2020-12-31 | 68.64% | ₩28.36 Billion | ₩41.32 Billion | -4.39pp |
| 2019-12-31 | 73.03% | ₩30.47 Billion | ₩41.72 Billion | +12.24pp |
| 2018-12-31 | 60.79% | ₩25.92 Billion | ₩42.64 Billion | +44.14pp |
| 2017-12-31 | 16.65% | ₩3.30 Billion | ₩19.84 Billion | -2.89pp |
| 2016-12-31 | 19.54% | ₩4.02 Billion | ₩20.58 Billion | -- |